Enliven Therapeutics Reports $103.7 Million Net Loss for 2025, Focuses on ELVN-001 Development

Enliven Therapeutics, Inc. (ELVN) reported a net loss of $103.7 million for the year ended December 31, 2025, compared to a net loss of $89.0 million for the previous year. The increased loss was primarily driven by higher internal research and development costs, particularly in stock-based compensation, and increased general and administrative expenses, also largely due to stock-based compensation. The company has not generated any revenue from product sales to date.

Research and development expenses totaled $85.9 million in 2025, up from $80.8 million in 2024. This increase was primarily due to higher internal research and development costs, consisting of $4.3 million in stock-based compensation, $3.6 million in salaries and benefits, and $0.3 million in other internal costs. This increase was partially offset by lower external research and development costs, driven by a decrease of $12.8 million in ELVN-002 costs due to the company's intention not to pursue development beyond 2025 as it explores strategic alternatives for the program, partially offset by increases of $7.8 million in ELVN-001 costs due to clinical progression and $1.9 million in other external costs primarily related to higher research costs. General and administrative expenses rose to $33.8 million in 2025 from $23.8 million in 2024, primarily due to a $9.6 million increase in stock-based compensation and a $0.4 million increase in professional fees and other costs.

The company's key operational focus remains on advancing ELVN-001, a BCR-ABL tyrosine kinase inhibitor, through clinical development. Updated clinical data from the ENABLE trial, a Phase 1 study in heavily pretreated patients with CML, were presented at the European Hematology Association (EHA) 2025 Congress and the American Society of Hematology (ASH) 2025 Annual Meeting and Exposition. The company plans to initiate ENABLE-2, a 2L+ Phase 3 pivotal trial, in the second half of 2026. In May 2025, the company decided to explore strategic alternatives for ELVN-002 to prioritize ELVN-001. As of December 31, 2025, Enliven had 60 full-time employees, with 45 engaged in research and product development and clinical activities.

Looking ahead, Enliven anticipates that its existing cash, cash equivalents, and marketable securities, totaling $462.6 million as of December 31, 2025, will be sufficient to fund its planned operating expenses and capital expenditure requirements into the first half of 2029. The company expects to continue to incur significant expenses as it progresses its clinical programs, expands its research pipeline, and operates as a public company. Enliven may seek additional funding through equity or debt financings, strategic collaborations, or other arrangements.